

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
November 5, 2014
MINUTES

1. Call to Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, November 5, 2014.

2. Welcome

Edward Behling, MD, called the meeting to order and welcomed members, guests, and staff members.

Dr. Behling opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

3. Committee Members Present:

Gregory Browning, MD
James Lindsey, MD

Tan Platt, MD
Edward Behling, MD

Jony Bollinger, MD
Thomas Phillips, R.Ph.

SC DHHS Staff:

Bryan Amick, PharmD, MBA
Jim Bradford, MD
Damian Bridges
Emma Husby
Constance Holloway, JD

Magellan Medicaid Admin:

Lisa Correll, PharmD
Lori Ash

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, August 6, 2014

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. Public Comment

Company	Speaker	Drug/Class

† No speakers

C. Drug Classes for Review

Lisa Correll led the discussion for the following drug classes:

Classes for Re-Review

- Anticonvulsants
- Antihistamines/Anticholinergic Nasal Agents
- Multiple Sclerosis Agents (Injectable)

Classes for Review

- Antiallergens (Sublingual)

The chart below represents the recommendations from the P & T Committee:

ANTICONVULSANTS, CARBAMAZEPINE DERIVATIVES	
Preferred	Non-Preferred
Carbamazepine (all dosage forms)	Equetro®
Epitol®	Aptiom®
Oxcarbazepine	Carbatrol®
	Tegretol/XR®
	Trileptal®
	Oxtellar XR®

ANTICONVULSANTS, SECOND GENERATION	
Preferred	Non-Preferred
Gabapentin	*Banzel®
Lamotrigine	*Fycompa®
Lamictal® ODT	*Gabitril®
Levetiracetam	Keppra®
Lyrica®	Lamictal®
Topiramate	Neurontin®
Zonisamide	*Onfi®
	*Potiga®
	Qudexy™
	*Sabril®
	Topamax®
	Trokendi™

ANTICONVULSANTS, SECOND GENERATION (continued)	
Preferred	Non-Preferred
	*Vimpat® Zonegran® <i>*Drugs require PA, no step therapy required</i>

ANTI-HISTAMINES/ANTICHOLINERGIC NASAL AGENTS	
Preferred	Non-Preferred
Astepro® Azestaline Ipratropium	Atrovent® Patanase®

MULTIPLE SCLEROSIS AGENTS (Injectable)	
Preferred	Non-Preferred
Avonex®/Admin Pack (interferon β-1a) Betaseron® (interferon β-1b) Copaxone® Extavia® (interferon β-1b) Rebif® (interferon β-1a)	Copaxone® 40mg

ANTIALLERGENS (Sublingual)	
Preferred	Non-Preferred
Grastek® Oralair® Ragwitek®	

5. **Old Business**

None

6. **New Business**

Emma Husby presented the “Healthy Connections Checkup” plan, an expansion of the Family Planning benefit which went live on August 1, 2014. The goals of the expanded plan are increased enrollment to 200,000 recipients by the end of SFY 2015, ensure access to and receipt of checkups and screenings, connect recipients to systems of care (strengthen referral system) and identify the health status of these recipients.

A limited benefit plan for coverage of Tuberculosis (TB) was presented to the Committee. This benefit will be limited to certain medications. Approximately 25% of deaths among HIV+ patients are due to TB. Tobacco use increases the risk of TB with approximately 20% of TB cases worldwide being attributed to smoking.

Coverage of vaccines will be expanded to include Shingles (Herpes Zoster) for recipients age 60 and above. HPV will be covered for HPV2 or 4 for females age 11 and 12. HPV4 will be covered for boys age 11 and 12. For adults, HPV will be covered for females age 26 and older and for males 21 or younger or males 22 – 26 who are in a high risk group or immunocompromised.

Current preferred vendors for diabetic strips and meters will remain in place as DHHS awaits ISO standards before moving forward with changes.

7. Resolved Items

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS.

- Antiallergens (Sublingual)
- Anticonvulsants
- Antihistamines/Anticholinergic Nasal Agents
- Multiple Sclerosis Agents (Injectable)

8. Closing Comments

The next meeting will be held on Wednesday, February 4, 2015, at 4:00 p.m.

9. Adjournment

The meeting adjourned at 5:13 p.m.